Overall survivals at 2 years of patients with nonadvanced disease; 116 patients received cyclosporine/methotrexate 63.6% (◊) and 97 patients received tacrolimus/methotrexate, 62.4% (□); absolute difference = 1.2%, 95% CI = −14.4 to 11.9 (P = .79, Wilcoxon).